1100 related articles for article (PubMed ID: 21112898)
21. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.
Linde C; Daubert C; Abraham WT; St John Sutton M; Ghio S; Hassager C; Herre JM; Bergemann TL; Gold MR;
Circ Heart Fail; 2013 Nov; 6(6):1180-9. PubMed ID: 24014828
[TBL] [Abstract][Full Text] [Related]
22. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study.
Linde C; Abraham WT; Gold MR; Daubert C;
J Am Coll Cardiol; 2010 Nov; 56(22):1826-31. PubMed ID: 21087711
[TBL] [Abstract][Full Text] [Related]
23. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.
Sunsaneewitayakul B; Sitthisook S; Sangwatanaroj S; Prechawat S; Songmuang SB
J Med Assoc Thai; 2007 Jul; 90(7):1458-66. PubMed ID: 17710992
[TBL] [Abstract][Full Text] [Related]
24. Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial.
Pouleur AC; Knappe D; Shah AM; Uno H; Bourgoun M; Foster E; McNitt S; Hall WJ; Zareba W; Goldenberg I; Moss AJ; Pfeffer MA; Solomon SD;
Eur Heart J; 2011 Jul; 32(14):1720-9. PubMed ID: 21609974
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
[TBL] [Abstract][Full Text] [Related]
26. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
[TBL] [Abstract][Full Text] [Related]
27. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.
Herweg B; Ilercil A; Cutro R; Dewhurst R; Krishnan S; Weston M; Barold SS
Am J Cardiol; 2007 Jul; 100(1):90-3. PubMed ID: 17599447
[TBL] [Abstract][Full Text] [Related]
28. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.
Hsu JC; Solomon SD; Bourgoun M; McNitt S; Goldenberg I; Klein H; Moss AJ; Foster E;
J Am Coll Cardiol; 2012 Jun; 59(25):2366-73. PubMed ID: 22698490
[TBL] [Abstract][Full Text] [Related]
29. Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT).
Martin DT; McNitt S; Nesto RW; Rutter MK; Moss AJ
Circ Heart Fail; 2011 May; 4(3):332-8. PubMed ID: 21350054
[TBL] [Abstract][Full Text] [Related]
30. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction?
Bond M; Mealing S; Anderson R; Dean J; Stein K; Taylor RS
Int J Cardiol; 2009 Nov; 137(3):206-15. PubMed ID: 18703244
[TBL] [Abstract][Full Text] [Related]
31. Dyssynchrony, contractile function, and response to cardiac resynchronization therapy.
Knappe D; Pouleur AC; Shah AM; Cheng S; Uno H; Hall WJ; Bourgoun M; Foster E; Zareba W; Goldenberg I; McNitt S; Pfeffer MA; Moss AJ; Solomon SD;
Circ Heart Fail; 2011 Jul; 4(4):433-40. PubMed ID: 21602574
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of implantable cardioverter defibrillators and cardiac resynchronization therapy in heart failure.
Freeman JV; Masoudi FA
Heart Fail Clin; 2013 Jan; 9(1):59-77. PubMed ID: 23168318
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
Smith T; Jordaens L; Theuns DA; van Dessel PF; Wilde AA; Hunink MG
Eur Heart J; 2013 Jan; 34(3):211-9. PubMed ID: 22584647
[TBL] [Abstract][Full Text] [Related]
34. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L;
Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923
[TBL] [Abstract][Full Text] [Related]
35. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
Ghali JK; Boehmer J; Feldman AM; Saxon LA; Demarco T; Carson P; Yong P; Galle EG; Leigh J; Ecklund FL; Bristow MR
J Card Fail; 2007 Nov; 13(9):769-73. PubMed ID: 17996827
[TBL] [Abstract][Full Text] [Related]
36. Cardiac resynchronization therapy for prevention of heart failure events in elderly patients with left ventricular dysfunction.
Dotsenko O; Barsheshet A; Huang DT
Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1319-27. PubMed ID: 23190070
[TBL] [Abstract][Full Text] [Related]
37. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
38. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
39. The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades.
Bogale N; Witte K; Priori S; Cleland J; Auricchio A; Gadler F; Gitt A; Limbourg T; Linde C; Dickstein K;
Eur J Heart Fail; 2011 Sep; 13(9):974-83. PubMed ID: 21771823
[TBL] [Abstract][Full Text] [Related]
40. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
Lindenfeld J; Feldman AM; Saxon L; Boehmer J; Carson P; Ghali JK; Anand I; Singh S; Steinberg JS; Jaski B; DeMarco T; Mann D; Yong P; Galle E; Ecklund F; Bristow M
Circulation; 2007 Jan; 115(2):204-12. PubMed ID: 17190867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
